E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
ST segment resolution as a tool for assessing the efficacy of reperfusion therapy
TL;DR: This review focuses on four interrelated roles for ST segment monitoring: the assessment of epicardial reperfusion and the identification of candidates for rescue percutaneous coronary intervention; the evaluation of microvascular and tissue-level reperFusion; the determination of prognosis early after fibrinolytic therapy; and the use of ST segment resolution to compare different reperfusions regimens.
Journal ArticleDOI
Reduction of Experimental Myocardial Infarct Size by Corticosteroid Administration
TL;DR: Pharmacological doses of hydrocortisone prevent myocardial cells from progressing to ischemic necrosis even when administration is initiated 6 h after coronary occlusion, showing that over one third of the sites were protected from undergoing necrosis due to the intervening hydroc Cortisone treatment.
Journal ArticleDOI
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.
Gregory D. Lewis,Rajeev Malhotra,Adrian F. Hernandez,Steven McNulty,Andrew L. Smith,G. Michael Felker,W.H. Wilson Tang,Shane J. LaRue,Margaret M. Redfield,Marc J. Semigran,Michael M. Givertz,Peter Van Buren,David J. Whellan,Kevin J. Anstrom,Monica R. Shah,Patrice Desvigne-Nickens,Javed Butler,Eugene Braunwald +17 more
TL;DR: The results do not support use of oral iron supplementation in patients with HFrEF and iron deficiency, and high-dose oral iron did not improve exercise capacity over 16 weeks.
Journal ArticleDOI
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial
Christopher P. Cannon,Carolyn H. McCabe,Robert G. Wilcox,Anatoly Langer,Abraham Caspi,Peter Berink,Jose Lopez-Sendon,Jiri Toman,Andrew Charlesworth,Robert J. Anders,John C. Alexander,Allan M. Skene,Eugene Braunwald +12 more
TL;DR: Fixed-dose orbofiban failed to reduce major cardiovascular events and was associated with increased mortality in this broad population of patients with acute coronary syndromes; however, a benefit was observed among patients who underwent percutaneous coronary intervention.
Journal ArticleDOI
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.
Torbjørn Omland,Torbjørn Omland,Marc A. Pfeffer,Marc A. Pfeffer,Scott D. Solomon,Scott D. Solomon,James A. de Lemos,Helge Røsjø,Helge Røsjø,Jūratė Šaltytė Benth,Jūratė Šaltytė Benth,Aldo P. Maggioni,Michael J. Domanski,Jean L. Rouleau,Jean L. Rouleau,Marc S. Sabatine,Marc S. Sabatine,Eugene Braunwald,Eugene Braunwald,Peace Investigators +19 more
TL;DR: In patients with stable CAD, high-sensitivity cardiac troponin I concentrations are associated with cardiovascular risk independently of conventional risk markers and hs-TnT.